De novo substitutions of TRPM3 cause intellectual disability and epilepsy

David A. Dyment1,2 · Paulien A. Terhal3 · Cecilie F. Rustad4 · Kristian Tveten5 · Christopher Griffith6 · Parul Jayakar7 · Marwan Shinawi8 · Sara Ellingwood9 · Rosemarie Smith9 · Koen van Gassen3 · Kirsty McWalter10 · A. Micheil Innes11 · Matthew A. Lines1,2

Received: 18 January 2019 / Revised: 26 April 2019 / Accepted: 25 June 2019 / Published online: 5 July 2019 © The Author(s) 2019. This article is published with open access

Abstract
The developmental and epileptic encephalopathies (DEE) are a heterogeneous group of chronic encephalopathies frequently associated with rare de novo nonsynonymous coding variants in neuronally expressed genes. Here, we describe eight probands with a DEE phenotype comprising intellectual disability, epilepsy, and hypotonia. Exome trio analysis showed de novo variants in TRPM3, encoding a brain-expressed transient receptor potential channel, in each. Seven probands were identically heterozygous for a recurrent substitution, p.(Val837Met), in TRPM3’s S4–S5 linker region, a conserved domain proposed to undergo conformational change during gated channel opening. The eighth individual was heterozygous for a proline substitution, p.(Pro937Gln), at the boundary between TRPM3’s flexible pore-forming loop and an adjacent alpha-helix. General-population truncating variants and microdeletions occur throughout TRPM3, suggesting a pathomechanism other than simple haploinsufficiency. We conclude that de novo variants in TRPM3 are a cause of intellectual disability and epilepsy.

Introduction
The developmental and epileptic encephalopathies (DEE) are a heterogeneous group of disorders characterized by epilepsy with comorbid intellectual disability (ID). Rare nonsynonymous coding variants in genes encoding ion channels, cell-surface receptors, and other neuronally expressed proteins are identifiable in one about quarter of affected individuals [1–3]. Most identified variants in individuals with DEE are in-frame, de novo, and recurrent across unrelated kindreds [2].

Transient receptor potential (TRP) channels are a superfamily of gated cation channels sensitive to a variety of physical and chemical stimuli [4]. Seven subfamilies are recognized [5]. TRP channels are implicated in several Mendelian disorders, including polycystic kidney disease (OMIM #613095), mucolipidosis type IV (#252650), amyotrophic lateral sclerosis–dementia–parkinsonism

1 Children’s Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, ON, Canada
2 Department of Pediatrics, University of Ottawa, Ottawa, ON, Canada
3 Department of Genetics, University Medical Centre Utrecht, Utrecht, the Netherlands
4 Department of Medical Genetics, Oslo University Hospital, Oslo, Norway
5 Department of Medical Genetics, Telemark Hospital Trust, Skien, Norway
6 University of South Florida, Tampa, FL, USA
7 Nicklaus Children’s Hospital, Miami, FL, USA
8 Department of Pediatrics, Division of Genetics and Genomic Medicine, Washington University School of Medicine, St. Louis, MO, USA
9 Department of Pediatrics, Division of Genetics, Maine Medical Center, Portland, ME, USA
10 GeneDx, Gaithersburg, MD, USA
11 Department of Medical Genetics and Alberta Children’s Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
complex (#105500), and others [5]. All TRP proteins share a common six-transmembrane-helix architecture with four-fold radial symmetry, distinct voltage-sensing and pore-forming domains, and variable N- and C-terminal cytoplasmic tails [4]. Some TRP proteins mediate sensory stimuli, e.g., noxious heat (TRPV1, TRPM3, and TRPA1) and cold (TRPM8); others are receptor-operated, and/or responsive to cellular stimuli including osmolarity, intracellular calcium, and/or chemical ligands [4].

In this study, we present eight individuals with a neurodevelopmental phenotype comprising ID, hypotonia, epilepsy (seven individuals), and a recognizable craniofacial gestalt; exome sequencing showed de novo substitutions of a TRP (melastatin-related) channel, TRPM3, in each. Seven of eight probands were heterozygous for a recurrent substitution, NM_020952.4:c.2509G>A, NP_066003.3:p.(Val837Met), altering a conserved residue previously implicated in channel gating. We propose that de novo substitutions of TRPM3 are a cause of ID and epilepsy.

Materials and methods

All procedures were in accord with the Declaration of Helsinki. Following suitable informed consent, exome sequencing of each proband plus their unaffected parents was performed on an accredited clinical basis according to standard protocols. Cohort assembly was accomplished by distributed case-matching in GeneMatcher [6]. Clinical and genetic data were provided by individual physician coauthors in accordance with local research and ethics requirements. The variants are deposited in ClinVar with accession numbers SCV000891785 and SCV000891786.

Results

Clinical findings

The probands are eight unrelated individuals with a symptom complex comprising moderate-to-severe global developmental delay (eight individuals), hypotonia or mixed tone abnormality (eight individuals), electrographically confirmed epilepsy (seven individuals), and/or variable minor anomalies (Table 1). Seizures corresponded to several clinical types (absence, generalized tonic-clonic, infantile spasms, and subclinical, including electrographic status epilepticus of sleep), were noted in infancy or early childhood, and were generally responsive to standard medical management. Electroencephalography showed nonspecific epileptiform activity. Brain MRI was normal in six individuals, and showed nonspecific volume loss in two individuals. Other associated anomalies, each observed in a minority of probands, included: Strabismus (four individuals), scoliosis (three individuals), talipes equinovarus (two individuals), athetoid movements in infancy (two individuals), C1 vertebral anomalies (two individuals), pectus excavatum (one individual), cryptorchidism (one individual), microopenis (one individual), and hip dysplasia (one individual). There was no consistent growth phenotype. The craniofacial gestalt was nondysmorphic, although shared features included a broad forehead, prominent nasal root, bulbous nasal tip, short philtrum, micrognathia, and prominent lobule of the ear (Fig. 1). One individual was described to have a heightened threshold for pain; a second individual had a history of repeated handwashing with scalding water. In no case was altered heat or pain sensitivity the primary reason for referral.

Genetic investigations

All individuals remained undiagnosed following standard genetic investigations, including genomic microarray (eight of eight individuals), Fragile X testing (six of eight individuals), and/or ID panel testing (three of eight individuals). Each kindred (proband and parents) next underwent clinical exome trio analysis, followed by distributed case-matching of genetically and phenotypically like patients using GeneMatcher [6]. Interestingly, seven individuals (1–7) were each heterozygous for the specific de novo substitution TRPM3 (NM_020952.4:c.2509G>A, NP_066003.3:p.(Val837Met). This change is not represented in GnomAD, and is predicted to be damaging (scaled CADD score 25.4; SIFT score 0.000; PolyPhen-2 score 0.998) [7–10]. The ACMG categorization of this variant is “pathogenic” on the basis of criteria PS2, PS4, PM1, PM2, and PP3 [11]. The eighth (final) individual was heterozygous for a private substitution, c.2810C>A, p.(Pro937Gln), observed once in GnomAD (allele frequency: \(3.98 \times 10^{-6}\)) and predicted to be damaging (scaled CADD score 28.8; SIFT score 0.000; PolyPhen-2 score 1.000). This variant meets ACMG criterion PS2, and is categorized as a variant of unknown significance. Of note, review of the other de novo coding variants in individual 8 further demonstrated a heterozygous splice-acceptor site deletion in the DNA damage-response protein DDB1 [(NM_001923.4):c.550-4_554delCCAGGCC]. Although DDB1 variants are not, as far as we are aware, directly implicated in any human disease, the TRPM3 variant in individual 8 remains an unclassified variant pending additional reports.

Public databases confirm that heterozygous loss-of-function variants of TRPM3 are observed in the general population. For instance, heterozygous gnomAD truncating variants occur in 18 of 25 canonical coding exons, and truncating variants are nondepleted as a proportion of all coding variants (ExAC pLI statistic = 0.00%) [7]. Moreover, in DGV [12], copy-loss CNVs intersect multiple
Table 1 Clinical and molecular characteristics

| Individual | 1     | 2     | 3     | 4     | 5     | 6     | 7     | 8     |
|------------|-------|-------|-------|-------|-------|-------|-------|-------|
| **TRPM3 variant** |       |       |       |       |       |       |       |       |
| cDNA (NM_020952.4) | c.2509G>A | c.2509G>A | c.2509G>A | c.2509G>A | c.2509G>A | c.2509G>A | c.2509G>A | c.2810C>A |
| Polypeptide (NP_066003.3) | p.(Val837Met) | p.(Val837Met) | p.(Val837Met) | p.(Val837Met) | p.(Val837Met) | p.(Val837Met) | p.(Pro937Gln) |       |
| Genomic DNA (NC_000009.11) | g.73213379C>T | g.73213379C>T | g.73213379C>T | g.73213379C>T | g.73213379C>T | g.73213379C>T | g.73213379C>T | g.73168145G>T |
| Zygosity | Heterozygous | Heterozygous | Heterozygous | Heterozygous | Heterozygous | Heterozygous | Heterozygous | Heterozygous |
| Segregation | De novo | De novo | De novo | De novo | De novo | De novo | De novo | De novo |
| **Clinical features** |       |       |       |       |       |       |       |       |
| Gestation (weeks) | 38 | 40 | 42 | 39 | 38 + 3 | 40 | 39 | Term |
| Perinatal history | C/S | N | N | N | N | C/S | C/S (repeat) |       |
| Birth weight (kg) | NR | 3.6 | 3.2 | 3.48 | 3.378 | 3.89 | 3.1 | 2.9 |
| Sex | M | M | F | M | M | M | F |       |
| Age (years) | 16 | 4.75 | 6 | 5.9 | 6.25 | 28 | 38 | 8.1 |
| Height (cm) | 164.5 (Z = -1.0) | 105.1 (Z = -0.7) | 110 (Z = -1.0) | 117 (Z = +0.3) | 116 (Z = -0.3) | NR | 169.5 (Z = -1.3) | 115.7 (Z = -2.0) |
| Weight (kg) | 73.3 (Z = +1.0) | 17.6 (Z = -0.1) | 17.8 (Z = -0.9) | 24.5 (Z = +1.4) | 22 (Z = +0.3) | NR | 63.2 (Z = -1.0) | 27.8 (Z = +0.6) |
| BMI (kg/m²) | 27.1 (Z = +1.8) | 15.9 (Z = +0.5) | 14.7 (Z = -0.4) | 17.9 (Z = +1.7) | 16.3 (Z = +0.7) | NR | 22.1 (Z = -0.0) | 22.3 (Z = +2.0) |
| OFC (cm) | 55.8 (15 years, 8 months) (Z = +0.2) | 49.5 (Z = -0.8) | 51 (Z = +0.2) | 55 (Z = +2.1) | 53.2 (Z = +0.7) | 56 (Z = 0) | 57 (Z = +0.5) | 52 (Z = +0.2) |
| Developmental delay/intellectual disability | + (Severe) | + (Moderate) | + (Moderate-to-severe) | + (Severe) | + (Severe) | + (Severe) | + (Moderate) | + (Moderate-to-severe) |
| Ambulate independently (age achieved) | + (5 years) | + (With walker) (3 years) | + (With walker) | + (4.5 years) | − | + (4 years) | + (3.5 years) |       |
| Any speech (age attained) | + (5 years) | − | − | − | − | + (5 years) | + (2.5 years) |       |
| Combine words/signs | + | − | − | − | − | + (Signs) | + (Sentences) |       |
| Toilet independently (age attained) | + (9 years) | − | − | − | − | − | − | NR (4 years) |
| Autism-like features | + | NR | + | + | + | − | NR | − |
| Electrophysiologically confirmed seizures | + | + | + | + | + | + | Unconfirmed | + |
| Seizure types | Absence | Infantile spasms | GTC | Subclinical, including ESES | NR | Absence and GTC | Absence | Absence |
| Individual | Age of first clinical seizure | Current anticonvulsant therapy | Age of last clinical seizure | Hypotonia | Craniofacial gestalt Morphological features | Other clinical features | Brain MRI | Apparent heat or pain insensitivity |
|------------|-------------------------------|-------------------------------|-------------------------------|-----------|---------------------------------------------|------------------------|-----------|----------------------------------|
| Individual 1 | Absence-like episodes in infancy; first documented EEG abnormalities at 7 years | Levetiracetam (initial); none (current) | NR (untreated follow-up EEG at age 15 was normal) | + | Nondysmorphic | C1 spinal stenosis; Chiari I malformation; scoliosis; torticollis; plagiocephaly; thickened filum terminale; bilateral talipes equinovarus; strabismus (exotropia OU) | Normal | + (Heat) |
| Individual 2 | EEG abnormalities at 3 years | NR | 11 months | + | Nondysmorphic | EMG/ NCS normal | Normal | NR |
| Individual 3 | Absence-like episodes in infancy; first documented EEG abnormalities at 7 years | NR | 9 months | + | Nondysmorphic | - | Normal | NR |
| Individual 4 | EEG abnormalities at 3 years | NR | <1 year | + | Nondysmorphic | Strabismus | Normal | NR |
| Individual 5 | EEG abnormalities at 3 years | Levetiracetam (with improvement in ESES) | 26 years (EEG remains pathological with diffuse high-amplitude activity) | + | Nondysmorphic | Cryptorchidism, micropenis, bilateral talipes equinovarus | Normal | NR |
| Individual 6 | EEG abnormalities at 3 years | None | NR | + (mixed tone abnormality) | Distinctive | Neonatal hypoglycemia; unilateral hip dysplasia; scoliosis | Normal | NR |
| Individual 7 | EEG abnormalities at 3 years | Lamotrigine | 6 years | + | Nondysmorphic | Atlanto-occipital fusion, strabismus (exotropia), hands held 'fisted' until 9 months, athetoid movements in infancy, pes planus | Normal | NR |
| Individual 8 | EEG abnormalities at 3 years | Levetiracetam | NR | Distinctive | Nondysmorphic | Choreoathetoid movements in infancy (age 5 months), strabismus, scoliosis | Normal | NR |
constitutive coding exons of TRPM3. In contrast, the gnomAD missense variation constraint metric for TRPM3 ($Z = +3.18$) suggests relative intolerance for in-frame substitution. Because (i) TRPM3 variants were non-randomly distributed in our cohort and (ii) functional hemizygosity of TRPM3 appears tolerated in general-population controls, we reasoned that simple haploinsufficiency was unlikely to be the mechanism of disease in our cohort. To predict the functional consequences of the variants in our patients, we modeled TRPM3 on the recently determined structure [13] of TRPM7 (Fig. 2). Like other TRP channels, TRPM7 is a radial tetramer with spatially distinct voltage-sensing and pore-forming domains (encoded by helices S1–S4 and S5, S6, respectively). Between voltage-sensing and pore-forming domains resides the TRP domain, a conserved "switch" region [13]. The model of TRPM3 suggests at least four hypotheses regarding the functional consequences of a valine-to-methionine substitution at position 837. Firstly, Val837 occupies a crucial position in TRPM3’s S4–S5 linker, a conserved helix which interacts with the TRP domain during gating [13, 14]. In TRPM3, a hydrogen bond is predicted between Val837 and Arg978 of the TRP domain; in TRPM7, the analogous bond (Val982-Arg1115) is essential and even conservative substitutions (e.g., p.Arg1115Gln) render the channel inactive [13, 15]. Secondly, TRPM3 is unique among TRP proteins in that its voltage-sensing domain contains a second, non-canonical, permeation pathway distinct from the central channel pore [16, 17]. Non-canonical conductance in TRPM3 can be abolished by mutations at any of the helix IV residues Trp827, Arg830, and Asp833, or Gly836, the latter being immediately adjacent to Val837 [17]. Thirdly, TRPM3 is among several TRP proteins responsive to phosphoinositides, and Arg978 is one of three TRP domain residues essential for phosphoinositide responsiveness [15, 18]. Fourthly, the tetrameric structure of TRP channels presents the possibility of structural dominant negativity by direct interaction of mutant and nonmutant subunits.

The case for pathogenicity of the p.Pro937Gln variant, observed only once in our cohort, is less clear. This substitution of a conserved, “helix-breaking” proline at the N-terminal extreme of helix S6 is predicted to extend helix S6 by one half-rotation, shortening and reanchoring the flexible pore-forming S5–S6 loop. This variant is regarded as a variant of unclear clinical significance, pending confirmation in additional probands.

**Discussion**

In this report, we present eight individuals with ID, hypotonia, epilepsy (seven individuals), and de novo
substitutions of TRPM3. The primary manifestations of this disorder are nonspecific, and we anticipate that panel- or exome-based sequencing is likely to be the typical means of diagnosis. Notwithstanding a few prior reports describing TRPM3 variation in humans, this study is the first to definitively assign a clinical phenotype to this gene in multiple unrelated probands. In 2014, the substitution TRPM3 (NM_020952):c.195A>G, p.(Ile65Met) was identified in an autosomal dominant glaucoma and cataract kindred linked to 9p13-q21 [19]. Although the TRPM3 variant did cosegregate with the affected haplotype, the critical region was large (~40 Mb; 114 genes), and causality was not established. Secondly, we are aware of a case report of brothers with Becker muscular dystrophy, autism, and a partial (nine-exon) TRPM3 deletion; however, the deletion did not cosegregate with disease [20]. Thirdly and finally, we know one prior report of a Kabuki-like syndrome in a single individual with a ~1.3Mbp microdeletion encompassing TRPM3 and three other genes; however, segregation was not assessed, as parents were unavailable [21]. This report is therefore the first to show a consistent TRPM3-related clinical phenotype across multiple unrelated kindreds.

TRPM3 is highly expressed in the brain in humans and other vertebrates [22]. In the developing rat brain, TRPM3 is initially restricted to neurons, but as myelination progresses expression shifts to oligodendrocytes, in which it mediates a calcium current responsive to D-erythro-sphingosine (a byproduct of myelin sphingolipid biosynthesis) [23]. The patients in this study did not show differences in cerebral myelination, although a minority of patients did show nonspecific cerebral white matter volume loss.

A well-characterized function of TRPM3 in the literature is its role in thermal nociception. Together with the capsaicin receptor, TRPV1, and the allyl isothiocyanate (wasabi) receptor, TRPA1, TRPM3 is one of three TRP channels required for noxious heat sensation in thermosensory neurons [24]. In mouse, TRPM3 is expressed in sensory neurons from dorsal root and trigeminal ganglia, and Trpm3−/− mice display attenuated nocifensive behavior after heat or dermal pregnenolone sulfate injection [25]. In this study, abnormal pain perception was endorsed in two individuals on specific questioning, but this feature was not consistent across the entire cohort, nor was it the presenting complaint in any patient. In the future, it may be interesting to objectively assess thermal nociception in TRPM3 patients by means of contact heat-evoked potentials, an electrophysiological technique requiring specific apparatus unavailable for use in this report.

This report is congruent with that of Hamdan et al. [2], who find that many of the identifiable variants in patients with DEE are recurrent, frame-preserving, de novo substitutions in channels or receptors expressed at the neuronal plasma membrane. Our findings suggest that TRPM3 is a locus for ID and epilepsy, and should be included in genetic panels targeting these indications.

Acknowledgements: The authors gratefully acknowledge the unique contributions of the patients and their families, without whom this work could not be completed.
Compliance with ethical standards

Conflict of interest KMW is an employee of GeneDx, Inc. The other authors declare that they have no conflict of interest.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Bowling KM, Thompson ML, Amaral MD, Finnila CR, Hiatt SM, Engel KL, et al. Genomic diagnosis for children with intellectual disability and/or developmental delay. Genome Med. 2017;9:43.
2. Hamdan FF, Myers CT, Cossette P, Lemay P, Spiegelman D, Laporte AD, et al. High rate of recurrent de novo mutations in developmental and epileptic encephalopathies. Am J Hum Genet. 2017;101:664–85.
3. Martínez F, Caro-Llopis A, Roselló M, Oltz S, Mayo S, Monfort S, et al. High diagnostic yield of syndromic intellectual disability by targeted next-generation sequencing. J Med Genet. 2016;54:87–92.
4. Clapham DE. TRP channels as cellular sensors. Nature. 2003;426:517–24.
5. Nilius B. TRP channels in disease. Biochim Biophys Acta. 2007;1772:805–12.
6. Sobreira N, Schiettecatte F, Valle D, Hamosh A. GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. Hum Mutat. 2015;36:928–30.
7. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285–91.
8. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4:1073–81.
9. Ramensky V. Human non-synonymous SNPs: server and survey. Nucleic Acids Res. 2002;30:3894–900.
10. Kircher M, Witten DM, Jain P, Oroak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46:310–5.
11. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405–24.
12. Macdonald JR, Ziman R, Yuen RKC, Feuk L, Scherer SW. The database of genomic variants: a curated collection of structural variation in the human genome. Nucleic Acids Res. 2013;42:D986–992.
13. Duan J, Li Z, Li J, Hulse RE, Santa-Cruz A, Valinsky WC, et al. Structure of the mammalian TRPM7, a magnesium channel required during embryonic development. Proc Natl Acad Sci USA. 2018;115:e8201–10.
14. Horn R. Coupled movements in voltage-gated ion channels. J Gen Physiol. 2002;120:449–53.
15. Xie J, Sun B, Du J, Yang W, Chen HC, Overton JD, et al. Phosphatidylinositol 4,5-bisphosphate (PIP2) controls magnesium gatekeeper TRPM6 activity. Sci Rep. 2011;1:146.
16. Held K, Voets T, Vriens J. TRPM3 in temperature sensing and beyond. Temperature. 2015;2:201–13.
17. Held K, Gruss F, Aloï VD, Janssens A, Ulens C, Voets T, et al. Mutations in the voltage-sensing domain affect the alternative permeation pathway in the TRPM3 channel. J Physiol. 2018;596:2413–32.
18. Tóth BI, Konrad M, Ghosh D, Mohr F, Halaszovich CR, Leitner MG, et al. Regulation of the transient receptor potential channel TRPM3 by phosphoinositides. J Gen Physiol. 2015;146:51–63.
19. Bennett TM, Mackay DS, Siegfried CJ, Shiels A. Mutation of the melastatin-related cation channel, TRPM3, underlies inherited cataract and glaucoma. PLoS ONE. 2014;9:e104000.
20. Pagnamenta AT, Holt R, Yusuf M, Pinto D, Wing K, Betancur C, et al. A family with autism and rare copy number variants disrupting the Duchenne/Becker muscular dystrophy gene DMD and TRPM3. J Neurodev Dis. 2011;3:124–31.
21. Kuniba H, Yoshiura K-I, Kondoh T, Ohashi H, Kurosawa K, Tonoki H, et al. Molecular karyotyping in 17 patients and mutation screening in 41 patients with Kabuki syndrome. J Hum Genet. 2009;54:304–9.
22. Grimm C, Kraft R, Sauerbruch S, Schultz G, Harteneck C. Molecular and functional characterization of the melastatin-related cation channel TRPM3. J Biol Chem. 2003;278:21493–501.
23. Hoffmann A, Grimm C, Kraft R, Goldbaum O, Wrede A, Nolte C, et al. TRPM3 is expressed in sphingosine-responsive myelinating oligodendrocytes. J Neurochem. 2010;114:654–65.
24. Vandewauw I, Clercq KD, Mulier M, Held K, Pinto S, Van Ranst N, et al. A TRP channel trio mediates acute noxious heat sensing. Nature. 2018;555:662–6.
25. Vriens J, Owssianik G, Hofmann T, Philipp SE, Stab J, Chen X, et al. TRPM3 is a nociceptor channel involved in the detection of noxious heat. Neuron. 2011;70:482–94.